Tactile Systems Technology (TCMD) AI Stock Analysis

• Market Cap: $657.24M
• Dividend Yield: N/A
• Average Volume (3M): 372.07K
• Price to Earnings (P/E): 34.9
• Beta (1Y): 0.65
• Revenue Growth: 9.28%
• EPS Growth: 21.00%
• Country: US
• Employees: 1,037
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.46
• Shares Outstanding: 22,438,927
• 10 Day Avg. Volume: 632,024
• 30 Day Avg. Volume: 372,072
• PEG Ratio: 2.06
• Price to Book (P/B): 3.03
• Price to Sales (P/S): 2.01
• P/FCF Ratio: 16.41
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 1.79
• Enterprise Value/Gross Profit: 2.38
• Enterprise Value/Ebitda: 15.46
• 1Y Price Target: $38.00
• Price Target Upside: 29.74% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 1.02
• Revenue Forecast (FY): $347.94M

• Rating: 61 Neutral
• Price Target: $30.00 ▲(2.42% Upside)
• Action: Reiterated Date: 02/20/26
• Date: Action: Reiterated 02/20/26

The score is anchored by solid profitability trends and a de-risked balance sheet, plus constructive 2026 guidance. Offsetting these positives are the sharply weak cash-flow profile in the financial statements, a mixed/neutral technical picture, and a relatively high P/E with no dividend support; Medicare prior-authorization uncertainty is an additional near-term overhang.

Positive Factors

Balance sheet strength & liquidity

The company finished 2025 debt-free with a sizable cash balance, providing a durable financial cushion to fund commercial expansion, R&D, and M&A without reliance on external debt. This materially reduces financial risk and increases strategic optionality over the next several quarters.

High gross margins and sustained profitability

Very strong gross margins (~76–78%) reflect favorable product economics for pneumatic compression systems and consumables, supporting sustainable operating leverage. These margins give the company room to invest in sales, clinical evidence and tech while preserving profitability over the medium term.

Portfolio expansion and TAM-enhancing acquisition

The LymphaTech acquisition and added 3D scanning capability broaden product offerings and support expansion into underdiagnosed patient segments (management cites ~20M symptomatic US patients). This strategically strengthens long-term growth drivers and payer engagement opportunities.

Negative Factors

Material cash-flow conversion weakness in 2025

A collapse in cash conversion—reported operating and free cash flow of zero in 2025—signals working-capital pressure or timing/reimbursement disruptions. This raises earnings-quality and self-funding risk, potentially constraining reinvestment or share-return plans until cash generation normalizes.

Medicare prior-authorization regulatory headwind

A new CMS prior-authorization requirement adds administrative steps and uncertainty to payer approvals for pneumatic compression devices. Because revenue relies heavily on third-party reimbursement, slower approvals or denials could structurally depress volumes and collections through the authorization transition period.

Rising operating expenses limiting margin upside

Significant increases in operating costs—sales, marketing and G&A—are being annualized into 2026, constraining near-term margin expansion despite strong gross margins. If productivity gains or revenue growth lag, sustained higher opex could compress operating leverage over multiple quarters.

Tactile Systems Technology Business Overview & Revenue Model

Company Description

Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.

How the Company Makes Money

Tactile Systems Technology generates revenue primarily through the sale of its medical devices and related products, which are often reimbursed by insurance providers, including Medicare. The company has established key partnerships with various healthcare systems and distributors, facilitating broader market access for its products. Additionally, TCMD benefits from a recurring revenue model, as patients may require ongoing supplies of disposables for their pneumatic compression devices, leading to repeat purchases. The company's strategic focus on innovation and expanding its product offerings also contributes to its revenue growth, along with efforts to increase awareness and adoption of its therapies among healthcare professionals.

Tactile Systems Technology Financial Statement Overview

Summary

Strong income statement and balance sheet are offset by a very weak cash-flow score. Revenue has grown steadily with solid gross margins and sustained profitability in 2023–2025, while leverage is low after significant debt reduction. However, the latest cash-flow data shows operating cash flow and free cash flow at $0 in 2025, raising material cash-conversion/earnings-quality risk until it normalizes.

Income Statement

Revenue has grown steadily from $187.1M (2020) to $329.5M (2025), with 2025 up 5.8% year over year, showing continued demand and scale. Profitability also improved materially versus the 2020–2022 loss-making period, with positive net income in 2023–2025 and a stable net margin around ~5.8% in 2024–2025. Gross margin remains strong (about ~68–74%), supporting a solid underlying product economics profile. Offsetting this, margins compressed versus the 2023 peak (net margin ~10.4% in 2023 down to ~5.8% in 2024–2025), and operating profitability is not consistently expanding, suggesting higher operating costs and/or mix pressure.

Balance Sheet

The balance sheet looks conservatively positioned with debt reduced sharply to ~$16.0M in 2025 from ~$50.4M in 2023, and leverage is low (debt-to-equity ~0.07 in 2025). Equity is sizable at ~$218.9M, providing a meaningful cushion, and returns on equity turned positive and remain solid in 2024–2025 after negative levels in 2021–2022. The main watch-out is that returns are below the 2023 level, indicating profitability is not as strong as it was at the recent peak, but overall financial risk from leverage appears limited.

Cash Flow

Cash generation is a key concern based on the latest data: 2025 shows operating cash flow and free cash flow at $0, with free cash flow down 100% and cash flow not covering reported earnings. This is a sharp reversal from 2023–2024, when operating cash flow was ~$35.9M–$40.7M and free cash flow was ~$33.4M–$38.1M, broadly supporting net income. The step-down in 2025 introduces uncertainty around working capital swings, reinvestment needs, or reporting quality of earnings until cash conversion normalizes.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	329.52M	292.98M	274.42M	246.78M	208.06M
Gross Profit	223.91M	216.69M	195.13M	175.98M	148.21M
EBITDA	35.92M	32.37M	26.42M	1.75M	1.92M
Net Income	19.09M	16.96M	28.52M	-17.87M	-11.81M
Balance Sheet
Total Assets	273.94M	297.92M	281.44M	255.00M	244.27M
Cash, Cash Equivalents and Short-Term Investments	83.45M	108.91M	75.23M	38.06M	40.71M
Total Debt	15.96M	45.11M	50.38M	72.23M	80.61M
Total Liabilities	55.04M	81.33M	87.80M	133.60M	116.04M
Stockholders Equity	218.90M	216.60M	193.64M	121.40M	128.23M
Cash Flow
Free Cash Flow	40.43M	38.15M	33.37M	3.29M	276.00K
Operating Cash Flow	42.81M	40.66M	35.85M	5.21M	2.63M
Investing Cash Flow	-2.54M	-2.50M	-2.48M	-1.91M	-82.18M
Financing Cash Flow	-51.20M	-4.82M	5.73M	-9.60M	59.93M

Tactile Systems Technology Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 29.29
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCMD, the sentiment is Positive. The current price of 29.29 is above the 20-day moving average (MA) of 28.41, above the 50-day MA of 29.11, and above the 200-day MA of 18.28, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 52.36 is Neutral, neither overbought nor oversold. The STOCH value of 29.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TCMD.

Tactile Systems Technology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VMD	72 Outperform	$330.76M	26.32	10.53%	―	18.90%	29.22%
TCMD	61 Neutral	$657.24M	34.91	8.77%	―	9.28%	21.00%
TLSI	54 Neutral	$302.65M	-2.51	―	―	49.52%	19.34%
CBLL	52 Neutral	$702.76M	-12.78	-30.83%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OM	51 Neutral	$63.83M	-0.51	-106.20%	―	4.65%	68.71%
SNWV	42 Neutral	$208.62M	-14.42	―	―	40.89%	-749.65%

Tactile Systems Technology Corporate Events

Tactile Systems Posts Strong Q4 Results and 2026 Outlook

On February 17, 2026, Tactile Medical reported that fourth-quarter 2025 revenue rose 21% year over year to $103.6 million, with gross margin improving to 78% and net income reaching $10.6 million as both lymphedema and airway clearance product lines drove growth. For full-year 2025, revenue increased 12% to $329.5 million, net income improved to $19.1 million and adjusted EBITDA climbed to $44.8 million, highlighting operational leverage.

The company strengthened its balance sheet by repaying the remaining $26.3 million term loan, ending 2025 debt-free with $83.4 million in cash, while returning $26.5 million to shareholders through stock repurchases. Strategically, Tactile Medical acquired LymphaTech to expand its lymphedema portfolio and digital 3D scanning capabilities, reported new clinical data on Flexitouch Plus, and issued a 2026 outlook calling for continued revenue and adjusted EBITDA growth, underscoring confidence in its market position and commercial momentum.

The most recent analyst rating on (TCMD) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Tactile Systems Technology stock, see the TCMD Stock Forecast page.